Giovanni Caforio - Bristol Myer COO, Director

BMYMP
 Stock
  

USD 1,100  0.50  0.0454%   

  Director
Dr. Giovanni Caforio M.D., serves as Chairman of the Board, Chief Executive Officer of the Company since May 02 2017. Dr. Caforio was our Chief Executive Officer since May 2015 and our Chairman since May 2017. He was our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014. From October 2011 to November 2013, he served as President, U.S. Dr. Caforio held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010. From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization
Age: 53  Director Since 2017  Ph.D    
212-546-4000  http://www.bms.com
Caforio is a member of the Board of Trustees of Hun School of Princeton, Business Roundtable, CEO Roundtable on Cancer and the Pharmaceutical Research and Manufacturers of America. With over 26 years of pharmaceutical industry experience, including more than 16 years at the company, Dr. Caforio has overseen the creation of a fully integrated worldwide commercial organization as part of our evolution into a diversified specialty biopharmaceutical company.

Giovanni Caforio Latest Insider Activity

Tracking and analyzing the buying and selling activities of Giovanni Caforio against Bristol Myer otc stock is an integral part of due diligence when investing in Bristol Myer. Giovanni Caforio insider activity provides valuable insight into whether Bristol Myer is net buyers or sellers over its current business cycle. Note, Bristol Myer insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bristol Myer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Bristol Myer Management Efficiency

Bristol Myer Squi has return on total asset (ROA) of 10.68 % which means that it generated profit of $10.68 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 2.97 %, meaning that it generated $2.97 on every $100 dollars invested by stockholders. Bristol Myer management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 7.39 B in total debt with debt to equity ratio (D/E) of 59.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bristol Myer Squi has a current ratio of 1.37, which is within standard range for the sector. Debt can assist Bristol Myer until it has trouble settling it off, either with new capital or with free cash flow. So, Bristol Myer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bristol Myer Squi sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bristol to invest in growth at high rates of return. When we think about Bristol Myer's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Wesley BushCisco Systems
2019
Karen ParkhillAmerican Express
2020
Susan HockfieldPfizer Inc
2020
Steven WestCisco Systems
1996
Brenton SaundersCisco Systems
2017
James QuinceyPfizer Inc
2020
Carl BassHP Inc
2015
Alice GastChevron Corp
2012
Rajiv GuptaHP Inc
2013
Scott GottliebPfizer Inc
2019
James UmplebyChevron Corp
2018
John StumpfChevron Corp
2010
Joseph EchevarriaPfizer Inc
2015
Michele BurnsCisco Systems
2003
Peter CherninAmerican Express
2006
Lynn PikeAmerican Express
2020
Ronald WilliamsAmerican Express
2018
Inge ThulinChevron Corp
2015
Robert DenhamChevron Corp
2004
Dan LittmanPfizer Inc
2018
Christopher YoungAmerican Express
2018
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people. Bristol Myer Squi [BMYMP] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Bristol Myer Squi Leadership Team

Elected by the shareholders, the Bristol Myer's board of directors comprises two types of representatives: Bristol Myer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myer's management team and ensure that shareholders' interests are well served. Bristol Myer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myer's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ann Powell, Chief Human Resource Officer, Senior Vice President
Togo West, Independent Director
Karen Vousden, Director
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer
Alan Lacy, Independent Director
Robert Bertolini, Independent Director
Jose Baselga, Independent Director
Charles Bancroft, CFO, Executive Vice President
Gerald Storch, Independent Director
Louis Schmukler, President - Global Manufacturing and Supply
Michael Grobstein, Independent Director
Christopher Boerner, Executive Vice President and Chief Commercial Officer
John Elicker, Senior Vice President - Public Affairs and Investor Relations
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer
Karen Santiago, Senior Vice President Controller
Giovanni Caforio, COO, Director
Vicki Sato, Independent Director
Emmanuel Blin, Senior Vice President Chief Strategy Officer
Joseph Caldarella, Senior Vice President Corporate Controller
Laurie Glimcher, Independent Director
Murdo Gordon, Executive Vice President Chief Commercial Officer
Lamberto Andreotti, CEO, Director
Thomas Lynch, Independent Director
Dinesh Paliwal, Independent Director
Lewis Campbell, Independent Director
Theodore Samuels, Independent Director
Samuel Moed, Senior Vice President - Strategic Planning and Analysis
Matthew Emmens, Independent Director
Ann Judge, Senior Vice President - Global Human Resources
Sandra Leung, General Counsel, Corporate Secretary
Paul Autenried, Senior Vice President - Enterprise Services, CIO
Francis Cuss, Executive Vice President Chief Scientific Officer
Paul Biondi, Senior Vice President Head - Business Development
Peter Arduini, Independent Director

Bristol Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Bristol Myer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bristol Myer without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Cryptocurrency Center Now

   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module

Pair Trading with Bristol Myer

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myer will appreciate offsetting losses from the drop in the long position's value.

Moving against Bristol Myer

0.8TSLATesla Inc TrendingPairCorr
0.58HDHome Depot Earnings Call  This WeekPairCorr
0.55DISWalt Disney Earnings Call  TodayPairCorr
The ability to find closely correlated positions to Bristol Myer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myer Squi to buy it.
The correlation of Bristol Myer is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myer Squi moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Bristol Myer Squi information on this page should be used as a complementary analysis to other Bristol Myer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Bristol OTC Stock analysis

When running Bristol Myer Squi price analysis, check to measure Bristol Myer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myer is operating at the current time. Most of Bristol Myer's value examination focuses on studying past and present price action to predict the probability of Bristol Myer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol Myer's price. Additionally, you may evaluate how the addition of Bristol Myer to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Is Bristol Myer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myer. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1804.8 B
The market value of Bristol Myer Squi is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myer's value that differs from its market value or its book value, called intrinsic value, which is Bristol Myer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myer's market value can be influenced by many factors that don't directly affect Bristol Myer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myer's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol Myer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.